Pulse Biosciences (PLSE) Total Non-Current Liabilities (2016 - 2025)

Pulse Biosciences' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $13.9 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 21.11% year-over-year to $13.9 million in Q4 2025; TTM through Dec 2025 was $13.9 million, a 21.11% decrease from a year earlier, with the FY2025 full-year figure at $13.9 million, down 21.11% from the prior year.
• Total Non-Current Liabilities retreated to $13.9 million in Q4 2025 per PLSE's latest filing, from $16.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $81.4 million in Q3 2022 and bottomed at $13.8 million in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $17.2 million (2022), against an average of $30.3 million.
• Across the five-year window, Total Non-Current Liabilities jumped 497.24% in 2021 and plunged 83.04% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $14.8 million in 2021, then jumped by 441.6% to $80.1 million in 2022, then plunged by 81.54% to $14.8 million in 2023, then gained by 18.95% to $17.6 million in 2024, then retreated by 21.11% to $13.9 million in 2025.
• Per Business Quant, the three latest PLSE Total Non-Current Liabilities figures stand at $13.9 million (Q4 2025), $16.1 million (Q3 2025), and $15.8 million (Q2 2025).